Synmosa Biopharma (4114): Kapitalflussrechnung
| Preis (11.09.2026) | 52W Hoch | 52W Tief |
| 29,5 Dollar (TWD) | 142,728 Dollar (TWD) | 26,791 Dollar (TWD) |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 37 Dollar (TWD) | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 509.639.270 | - | - |
Kennzahl in 1000 TWD | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Umsatz | 6.189.262 | 5.549.549 | 5.140.495 | 4.386.364 | 3.234.960 | 3.038.286 | 2.679.966 | 2.363.197 | 1.860.944 | 1.865.247 | 1.776.409 |
Cashflow aus operativer Geschäftstätigkeit | 411.573 | 780.622 | 511.929 | 630.247 | 444.294 | 254.402 | -44.882 | 15.996 | -5.194 | 236.484 | 23.602 |
▸ Operative Cashflow Marge | 6,65% | 14,07% | 9,96% | 14,37% | 13,73% | 8,37% | -1,67% | 0,68% | -0,28% | 12,68% | 1,33% |
Investitionsausgaben (CapEx) | 281.134 | 269.651 | 269.767 | 129.295 | 93.057 | 154.407 | 183.372 | 314.434 | 146.931 | 423.915 | 369.262 |
Cashflow aus Investitionstätigkeit | - | - | - | -69.334 | 83.902 | 34.499 | -598.787 | -42.031 | -740.000 | -1.038.920 | -449.305 |
Cashflow aus Finanzierungstätigkeit | - | - | - | - | -297.567 | -111.783 | 663.194 | 81.659 | 520.051 | 1.192.335 | 271.965 |
Freier Cashflow | 130.439 | 510.971 | 242.162 | 500.952 | 351.237 | 99.995 | -228.254 | -298.438 | -152.125 | -187.431 | -345.660 |
▸ Freie Cashflow Marge | 2,11% | 9,21% | 4,71% | 11,42% | 10,86% | 3,29% | -8,52% | -12,63% | -8,17% | -10,05% | -19,46% |
Ausgeschüttete Dividenden | -272.614 | -228.737 | -194.434 | -148.635 | -79.977 | -45.696 | -38.018 | -35.559 | -32.082 | -25.529 | -24.061 |
Neuausgabe und Rückkäufe von Stammaktien | - | - | - | -108.973 | -51.643 | -51.643 | - | -105.939 | -50.894 | - | - |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.